Commonwealth Equity Services
SBFM

Commonwealth Equity Services’s Sunshine Biopharma SBFM Stock Holding History

Commonwealth Equity Services’s Portfolio SBFM Stock Details SBFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,344
Closed -$14K – 4550
2026
Q1 		$14K Buy
+1,344
New +$15.8K ﹤0.01% 4271

Other funds holding SBFM

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
SFG
Strive Financial Group Carmel, Indiana $230M AUM
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Commonwealth Equity Services's SBFM Position: Q2 2026 in Review

Commonwealth Equity Services sold out of Sunshine Biopharma (SBFM) in Q2 2026, closing a stake of 1,344 shares — an estimated $14K sold.

Commonwealth Equity Services first reported a position in SBFM in Q1 2026 and held it in 1 quarter. The position peaked at $14K in Q1 2026. 9 funds tracked by Wall St. Rank hold SBFM as of Q2 2026.

  • Commonwealth Equity Services reported no remaining Sunshine Biopharma position as of Q2 2026 after selling out during the quarter.
  • Commonwealth Equity Services sold 1,344 Sunshine Biopharma shares in Q2 2026, an estimated $14K.
  • Commonwealth Equity Services first reported a position in Sunshine Biopharma in Q1 2026 and held it in 1 quarter.
  • Commonwealth Equity Services's Sunshine Biopharma position peaked at $14K in Q1 2026.
  • 9 funds tracked by Wall St. Rank held Sunshine Biopharma as of Q2 2026.

Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.